IN8bio, Inc. Files 8-K on Exit Costs and Other Events
Ticker: INAB · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $0.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, restructuring, disposal
TL;DR
IN8bio filed an 8-K detailing exit costs and other events as of Aug 30, 2024.
AI Summary
IN8bio, Inc. filed an 8-K on August 30, 2024, reporting costs associated with exit or disposal activities and other events. The company, formerly known as Incysus Therapeutics, Inc., is incorporated in Delaware and headquartered in New York. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates IN8bio is undergoing restructuring or divesting certain assets, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Filings related to exit or disposal activities often signal significant operational changes or financial challenges.
Key Players & Entities
- IN8bio, Inc. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former company name
- August 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal executive offices city and state
FAQ
What specific activities are associated with the exit or disposal mentioned in the filing?
The filing indicates costs associated with exit or disposal activities, but does not specify the exact nature of these activities in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 30, 2024.
What was IN8bio, Inc.'s former company name?
IN8bio, Inc.'s former company name was Incysus Therapeutics, Inc.
In which state is IN8bio, Inc. incorporated?
IN8bio, Inc. is incorporated in Delaware.
What is the address of IN8bio, Inc.'s principal executive offices?
The address of IN8bio, Inc.'s principal executive offices is 350 5th Avenue, Suite 5330, New York, New York 10118.
Filing Stats: 864 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-04 16:18:45
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
- $0.3 million — o incur one-time costs of approximately $0.3 million in connection with this workforce reduc
Filing Documents
- d855704d8k.htm (8-K) — 29KB
- d855704dex991.htm (EX-99.1) — 17KB
- 0001193125-24-213132.txt ( ) — 176KB
- inab-20240830.xsd (EX-101.SCH) — 3KB
- inab-20240830_lab.xml (EX-101.LAB) — 18KB
- inab-20240830_pre.xml (EX-101.PRE) — 11KB
- d855704d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated September 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: September 4, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)